The combined intervention including ADAM17 knockdown and eplerenone treatment provided an additional cardioprotective effect compared with that produced by monotherapy and produced no side effects, such as hyperkalemia, which was a crucial finding in the search for new treatments for DCM. Here, ADAM17 is linked to familial dilated cardiomyopathy.